Stablepharma Initiates Phase 2b Trial for Thermostable Tetanus-Diphtheria Vaccine

Stablepharma Ltd has begun its pivotal Phase 2b clinical trial by dosing the first participant for SPVX02, a thermostable tetanus-diphtheria (Td) booster vaccine. This vaccine utilizes StablevaX™ technology to eliminate the need for refrigeration, which could significantly improve global distribution and accessibility, particularly in regions with limited cold chain infrastructure. The trial follows positive Phase 1 results and is a crucial step towards commercialization.